Recursion Pharmaceuticals, Inc. RXRX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s return on equity?
- Recursion Pharmaceuticals, Inc. (RXRX) reported return on equity of -57.2% in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s return on equity changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s return on equity increased by 33.6% year-over-year, from -86.1% to -57.2%.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s return on equity?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s return on equity has grown at a 8.5% compound annual growth rate (CAGR), from -46.6% to -59.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.